Aspen Pharma Brasil

aspenpharma.com.br

Aspen Pharma Brazil is a subsidiary of Aspen Pharmacare, the leading brand in Africa and one of the 20 largest branded generic brand in the world. Aspen Pharmacare has 18 production plants in 14 countries on six continents, and supplies medicines to more than 150 countries. The Group officially entered the Brazilian drug market in 2009 after acquiring 100% of Cellofarm, headquartered in Rio de Janeiro. Aspen do Brasil's mission is to supply the domestic market, in addition to ensuring the Group's expansion in Latin America, focusing on growth through global acquisitions with other multinationals.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

DEARGEN ANNONUCES PATENT APPLICATION FOR A TNBC TARGET NOVEL DRUG CANDIDATE USING AI

Deargen Inc. | December 23, 2021

news image

Deargen, a company specializing in the development of novel NCE drugs using artificial intelligence, announced on the 22rd that it had discovered and synthesized a new anticancer target compound using its own AI platform and had already applied for a patent for it. Deargen has the technology to predict candidates for a novel drug without the 3D structure data of proteins. Deargen's technology, which uses amino acid sequence data rather than the structure information of protein...

Read More

BUSINESS INSIGHTS

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

news image

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More

MERCK TO SPIN OFF WOMEN’S HEALTH AND BIOSIMILAR DRUG BUSINESSES

The Globe and Mail | February 05, 2020

news image

Merck & Co Inc said on Wednesday it will spin off its women’s health, biosimilar drugs and older products into a separate publicly traded company as it tightens its focus on growth drivers like cancer drug Keytruda and vaccines. The new company’s assets currently make up around 15 per cent of Merck’s total sales and around half of its drugs that treat people. Merck will retain its animal health business, as well as drugs used for acute care in hospitals such as Bridion, whi...

Read More

BUSINESS INSIGHTS

NOVARTIS ANNOUNCES NEW ORGANIZATIONAL STRUCTURE TO ACCELERATE GROWTH STRENGTHEN PIPELINE AND INCREASE PRODUCTIVITY

Novartis Pharma AG | April 04, 2022

news image

Novartis announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade. “The simpler organizational model we are unveiling today is central to our growth strategy as it will make us more agile and competitive, enhance patient and customer orientation, unlock significant potential in our R&D pip...

Read More
news image

BUSINESS INSIGHTS

DEARGEN ANNONUCES PATENT APPLICATION FOR A TNBC TARGET NOVEL DRUG CANDIDATE USING AI

Deargen Inc. | December 23, 2021

Deargen, a company specializing in the development of novel NCE drugs using artificial intelligence, announced on the 22rd that it had discovered and synthesized a new anticancer target compound using its own AI platform and had already applied for a patent for it. Deargen has the technology to predict candidates for a novel drug without the 3D structure data of proteins. Deargen's technology, which uses amino acid sequence data rather than the structure information of protein...

Read More
news image

BUSINESS INSIGHTS

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More
news image

MERCK TO SPIN OFF WOMEN’S HEALTH AND BIOSIMILAR DRUG BUSINESSES

The Globe and Mail | February 05, 2020

Merck & Co Inc said on Wednesday it will spin off its women’s health, biosimilar drugs and older products into a separate publicly traded company as it tightens its focus on growth drivers like cancer drug Keytruda and vaccines. The new company’s assets currently make up around 15 per cent of Merck’s total sales and around half of its drugs that treat people. Merck will retain its animal health business, as well as drugs used for acute care in hospitals such as Bridion, whi...

Read More
news image

BUSINESS INSIGHTS

NOVARTIS ANNOUNCES NEW ORGANIZATIONAL STRUCTURE TO ACCELERATE GROWTH STRENGTHEN PIPELINE AND INCREASE PRODUCTIVITY

Novartis Pharma AG | April 04, 2022

Novartis announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade. “The simpler organizational model we are unveiling today is central to our growth strategy as it will make us more agile and competitive, enhance patient and customer orientation, unlock significant potential in our R&D pip...

Read More